Journal article

Risk of medication overuse headache across classes of treatments for acute migraine

Kristian Thorlund, Christina Sun-Edelstein, Eric Druyts, Steve Kanters, Shanil Ebrahim, Rahul Bhambri, Elodie Ramos, Edward J Mills, Michel Lanteri-Minet, Stewart Tepper

The Journal of Headache and Pain | BMC | Published : 2016


BACKGROUND: The most commonly prescribed medications used to treat migraine acutely are single analgesics, ergots, opioids, and triptans. Due to varying mechanisms of action across drug classes, there is reason to believe that some classes may be less likely than others to elicit Medication Overuse Headache (MOH) than others. We therefore aimed to determine whether certain classes of acute migraine drugs are more likely to elicit MOH than others. METHODS: A comprehensive systematic literature was conducted to identify studies of varying designs that reported on MOH within the considered treatment classes. Only studies that reported MOH according to the International Classification of Headach..

View full abstract

University of Melbourne Researchers


Funding Acknowledgements

The study was funded by Pfizer Inc. Redwood Outcomes conducted this study. Drs. Thorlund and Mills are founding partners of Redwood Outcomes and were paid consultants for conducting this study and for the development of this manuscript. Drs. Thorlund and Mills have previously consulted to Boehringer Ingleheim, Merck, Pfizer, Novartis, Janssen, Roche, Novo Nordisk, UCB, Sanofi, BTG, Bayer, Teva, Lundbeck, Lilly, and Gilead on systematic reviews and network meta-analysis. In addition, Drs. Thorlund and Mills have received grant funding from the Canadian Institutes of Health Research (CIHR) Drug Safety & Effectiveness Network to develop methods and educational materials on network meta-analysis. Eric Druyts, and Ping Wu are employees of Redwood Outcomes. Drs Bhambri and Ramos are full-time employees of Pfizer Inc. Dr. Lanteri-Milnet has received compensation from Allergan, Almirall SAS, Amgen, Astellas, AstraZeneca Pharmaceuticals, ATI, BMS, Boehringer, Boston Scientific, CoLucid, Convergence, Glaxo-SmithKline, Grunenthal, Lilly, Johnson & Johnson, Medtronic, Menarini, MSD, Pierre Fabre, Pfizer, ReckittBenckiser, Saint-Jude, Sanofi-Aventis, UCB, Zambon. Dr. Sun-Edelstein has received lecture fees from Pfizer and MSD. Dr. Tepper has received grant funding from Alder, Allergan, Amgen, ATI, ElectroCore, eNeura, GSK, Teva, Pernix, Optinose/Avanir/Otsuka; served as a consultant to Acorda, Allergan, Amgen, ATI, Avanir, Depomed, Impax, Pfizer, Scion Neurostim, Teva, Zosana; participated in speakers bureau activities for Allergan, Depomed, Impax, Pernix, Teva and Advisory activities for Allergan, Amgen, ATI, Avanir, Dr. Reddy's, Merck, Teva, Pfizer. Dr. Tepper further holds stock in ATI. Drs. Ebrahim and Kanters have nothing to disclose.